Grethe Å Ueland1,2,3, Paal Methlie1,2,3, Marianne Øksnes1,2,3, Hrafnkell B Thordarson3, Jørn Sagen1,4, Ralf Kellmann4, Gunnar Mellgren1,4, Maria Ræder5, Per Dahlqvist6, Sandra R Dahl7, Per M Thorsby7, Kristian Løvås1,2,3, Eystein S Husebye1,2,3. 1. Department of Clinical Science, University of Bergen, Bergen, Norway. 2. K.G. Jebsen Senter for Autoimmune Sykdommer, University of Bergen, Bergen, Norway. 3. Department of Medicine, Haukeland University Hospital, Bergen, Norway. 4. Hormone Laboratory, Haukeland University Hospital, Bergen, Norway. 5. Bergen Spesialistsenter, Bergen, Norway. 6. Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden. 7. Hormone Laboratory, Department of Medical Biochemistry, Oslo University Hospital Aker, Oslo, Norway.
Abstract
Background: The cosyntropin test is used to diagnose adrenal insufficiency (AI) and nonclassical congenital adrenal hyperplasia (NCCAH). Current cutoffs for cortisol and 17-hydroxyprogesterone (17-OHP) are derived from nonstandardized immunoassays. Liquid chromatography tandem mass spectrometry (LC-MS/MS) offers direct measurement of steroids, prompting the need to re-establish normal ranges. Objective: The goal of this study was to define cutoff values for cortisol and 17-OHP in serum by LC-MS/MS 30 and 60 minutes after intravenous administration of 250 µg tetracosactide acetate to healthy volunteers and to compare the results with LC-MS/MS with routine immunoassays. Methods: Cosyntropin testing was performed in healthy subjects (n = 138) and in patients referred for evaluation of adrenocortical function (n = 94). Steroids were assayed by LC-MS/MS and compared with two immunoassays used in routine diagnostics (Immulite and Roche platforms). The cutoff level for cortisol was defined as the 2.5% percentile in healthy subjects not using oral estrogens (n = 121) and for 17-OHP as the 97.5% percentile. Results: Cortisol cutoff levels for LC-MS/MS were 412 and 485 nmol/L at 30 and 60 minutes, respectively. Applying the new cutoffs, 13 of 60 (22%) subjects who had AI according to conventional criteria now had a normal test result. For 17-OHP, the cutoff levels were 8.9 and 9.0 nmol/L at 30 and 60 minutes, respectively. Conclusions: LC-MS/MS provides cutoff levels for cortisol and 17-OHP after cosyntropin stimulation that are lower than those based on immunoassays, possibly because cross-reactivity between steroid intermediates and cortisol is eliminated. This reduces the number of false-positive tests for AI and false-negative tests for NCCAH.
Background: The cosyntropin test is used to diagnose adrenal insufficiency (AI) and nonclassical congenital adrenal hyperplasia (NCCAH). Current cutoffs for cortisol and 17-hydroxyprogesterone (17-OHP) are derived from nonstandardized immunoassays. Liquid chromatography tandem mass spectrometry (LC-MS/MS) offers direct measurement of steroids, prompting the need to re-establish normal ranges. Objective: The goal of this study was to define cutoff values for cortisol and 17-OHP in serum by LC-MS/MS 30 and 60 minutes after intravenous administration of 250 µg tetracosactide acetate to healthy volunteers and to compare the results with LC-MS/MS with routine immunoassays. Methods: Cosyntropin testing was performed in healthy subjects (n = 138) and in patients referred for evaluation of adrenocortical function (n = 94). Steroids were assayed by LC-MS/MS and compared with two immunoassays used in routine diagnostics (Immulite and Roche platforms). The cutoff level for cortisol was defined as the 2.5% percentile in healthy subjects not using oral estrogens (n = 121) and for 17-OHP as the 97.5% percentile. Results:Cortisol cutoff levels for LC-MS/MS were 412 and 485 nmol/L at 30 and 60 minutes, respectively. Applying the new cutoffs, 13 of 60 (22%) subjects who had AI according to conventional criteria now had a normal test result. For 17-OHP, the cutoff levels were 8.9 and 9.0 nmol/L at 30 and 60 minutes, respectively. Conclusions: LC-MS/MS provides cutoff levels for cortisol and 17-OHP after cosyntropin stimulation that are lower than those based on immunoassays, possibly because cross-reactivity between steroid intermediates and cortisol is eliminated. This reduces the number of false-positive tests for AI and false-negative tests for NCCAH.
Authors: Jia Zhu; Florian Eichler; Alessandra Biffi; Christine N Duncan; David A Williams; Joseph A Majzoub Journal: Endocr Rev Date: 2020-08-01 Impact factor: 19.871
Authors: Sriram Gubbi; Lisa M Cordes; Joanna Klubo-Gwiezdzinska; Ravi A Madan; Lynnette K Nieman; James L Gulley; Jaydira Del Rivero Journal: Oncologist Date: 2020-11-23
Authors: Laura E Dichtel; Melanie Schorr; Claudia Loures de Assis; Elizabeth M Rao; Jessica K Sims; Kathleen E Corey; Puja Kohli; Patrick M Sluss; Michael J McPhaul; Karen K Miller Journal: J Clin Endocrinol Metab Date: 2019-10-01 Impact factor: 5.958
Authors: Femke Besemer; Cornelis Kramers; Kees Brinkman; Ad R M M Hermus; Antonius E van Herwaarden; David M Burger Journal: Int J Clin Pharm Date: 2020-03-05
Authors: G Grassi; V Morelli; F Ceriotti; E Polledri; S Fustinoni; S D'Agostino; G Mantovani; I Chiodini; M Arosio Journal: Hormones (Athens) Date: 2020-03-28 Impact factor: 2.885